EMI (Encore Medical) NonCurrent Deferred Liabilities: $0.00 Mil (As of Dec. 2025)


What is Encore Medical NonCurrent Deferred Liabilities?

Encore Medical EMI NonCurrent Deferred Liabilities is $0.00 Mil as of Dec. 2025.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Encore Medical's non-current deferred liabilities for the quarter that ended in Dec. 2025 was $0.00 Mil.

Encore Medical NonCurrent Deferred Liabilities Related Terms

Encore Medical NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Encore Medical's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Encore Medical NonCurrent Deferred Liabilities Chart

Encore Medical Annual Data
Trend Dec23 Dec24 Dec25
NonCurrent Deferred Liabilities
0.00 0.00 0.00

Encore Medical Quarterly Data
Dec23 Sep24 Dec24 Jun25 Sep25 Dec25
NonCurrent Deferred Liabilities Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
What does a NonCurrent Deferred Liabilities of $0.00 Mil mean?
Encore Medical (EMI) has a NonCurrent Deferred Liabilities of $0.00 Mil as of Dec. 2025. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Encore Medical and its competitors.
Is Encore Medical's NonCurrent Deferred Liabilities too high?
Encore Medical's current NonCurrent Deferred Liabilities is $0.00 Mil.
How does Encore Medical's NonCurrent Deferred Liabilities compare to ?
Encore Medical's NonCurrent Deferred Liabilities of $0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Medical Devices & Instruments company?
A good NonCurrent Deferred Liabilities depends on the Medical Devices & Instruments industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Encore Medical and its competitors. Encore Medical's current NonCurrent Deferred Liabilities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Encore Medical stock overvalued right now?
Encore Medical (EMI) has a current NonCurrent Deferred Liabilities of $0.00 Mil. The current NonCurrent Deferred Liabilities is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Encore Medical (EMI), the current NonCurrent Deferred Liabilities is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Encore Medical Business Description

Comparable Companies
Address 2975 Lone Oak Drive, Suite 140, Eagan, MN, USA, 55121
Encore Medical Inc develops, manufactures, and markets septal occlusion devices for the repair of certain cardiac defects. Its products have been implanted in approximately 35,000 patients outside the United States. Its closure device is designed to correct a cardiac defect, generally diagnosed in adulthood, known as a patent foramen ovale (PFO). The company also currently market and sell septal occlusion devices for the transcatheter closure of atrial septal defects (ASD).